{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T04:37:37Z","timestamp":1789879057262,"version":"4.0.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1995,1,1]],"date-time":"1995-01-01T00:00:00Z","timestamp":788918400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother. Pharmacol."],"published-print":{"date-parts":[[1995,1]]},"DOI":"10.1007\/s002800050252","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T08:03:26Z","timestamp":1030262606000},"page":"391-396","source":"Crossref","is-referenced-by-count":8,"title":["A pharmacogically guided phase I study of carboplatin in combination with methotrexate and vinblastine in advanced urothelial cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Etienne","family":"Chatelut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Chevreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Houin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Bugat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Canal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"50350391280_CR1","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/1097-0142(19921001)70:7<1974::AID-CNCR2820700727>3.0.CO;2-D","volume":"70","author":"J Bellmunt","year":"1992","unstructured":"Bellmunt J, Albaneil J, Gallego S, Ribas A, Vincente P, Carulla J, De Torres J, Morote J, Lopez M, Sol\u00e9 LA (1992) Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 70:1974","journal-title":"Cancer"},{"key":"50350391280_CR2","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burneil M, Boxall FE, Siddick ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748","journal-title":"J Clin Oncol"},{"key":"50350391280_CR3","first-page":"169","volume":"37","author":"C Chantler","year":"1969","unstructured":"Chantler C, Garnett ES, Parsons V, Veall N (1969) Glomerular filtration rate measurement in man by single injection method using 51Cr-EDTA. Clin Sci 37:169","journal-title":"Clin Sci"},{"key":"50350391280_CR4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockroft","year":"1976","unstructured":"Cockroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31","journal-title":"Nephron"},{"key":"50350391280_CR5","first-page":"5432","volume":"44","author":"MJ Egorin","year":"1984","unstructured":"Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, Aisner J (1984) Pharmacokinetics and dosage reduction of cis-diammine(l,l-cyclobutane dicarboxylo)-platinum in patients with impaired renal function. Cancer Res 44: 5432","journal-title":"Cancer Res"},{"key":"50350391280_CR6","first-page":"6502","volume":"45","author":"MJ Egorin","year":"1985","unstructured":"Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, Aisner J (1985) Prospective validation of a pharmacologically based dosing scheme for cis-diamminedichloroplatinum(II) analogue diamminecyclobutane dicarboxylatoplatinum. Cancer Res 45:6502","journal-title":"Cancer Res"},{"key":"50350391280_CR7","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.1986.4.10.1506","volume":"4","author":"M Eisenberger","year":"1986","unstructured":"Eisenberger M, Hornedo J, Silva H, Donehower R, Splaulding M, Van Echo D (1986) Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 4:1506","journal-title":"J Clin Oncol"},{"key":"50350391280_CR8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.1993.11.12.2295","volume":"11","author":"KR Hande","year":"1993","unstructured":"Hande KR (1993) Pharmacologic-based dosing of carboplatin: a better method. J Clin Oncol 11:2295","journal-title":"J Clin Oncol"},{"key":"50350391280_CR9","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1200\/JCO.1985.3.11.1463","volume":"3","author":"WG Harker","year":"1991","unstructured":"Harker WG, Meyers FJ, Freiha FS, Palmer JM, Shortliffe LD, Hannigan JF, McWhirter KM, Torti FM (1991) An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract: a Northern California Oncology Group study. J Clin Oncol 3:1463","journal-title":"J Clin Oncol"},{"key":"50350391280_CR10","first-page":"1665","volume":"29","author":"AM Imbert","year":"1983","unstructured":"Imbert AM, Pignon T, Lena N (1983) Methotrexate enzymatic assay with the use of centrifugal analyser Cobas-bio. Clin Chim Acta 29:1665","journal-title":"Clin Chim Acta"},{"key":"50350391280_CR11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1097\/00000421-199108000-00011","volume":"14","author":"J Klocker","year":"1991","unstructured":"Klocker J, Pont J, Schumor J, Pr\u00fcger J, Kienzer H (1991) Carboplatin, methotrexate and vinblastine (Carbo-MV) for advanced urothelial cancer: a phase II trial. Am J Clin Oncol 14:328","journal-title":"Am J Clin Oncol"},{"key":"50350391280_CR12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/0006-2944(77)90089-8","volume":"18","author":"AF LeRoy","year":"1977","unstructured":"LeRoy AF, Wehling ML, Sponseller HL, Friauf WS, Solomon RE, Dedrick RL (1977). Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med 18:184","journal-title":"Biochem Med"},{"key":"50350391280_CR13","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1200\/JCO.1993.11.10.1952","volume":"11","author":"V Lorusso","year":"1993","unstructured":"Lorusso V, Catino A, Leone B, Rabinovich M, Gargano G, Paradiso A, De Lena M (1993) Carboplatin plus ifosfamide as salvage treatment of epithelial ovarian cancer: a pilot study. J Clin Oncol 11: 1952","journal-title":"J Clin Oncol"},{"key":"50350391280_CR14","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0277-5379(87)90372-5","volume":"23","author":"Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer","year":"1987","unstructured":"Medical Research Council Working Party on Urological Cancer, Subgroup in Advanced Bladder Cancer (1987) A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder. Eur J Cancer Clin Oncol 23:375","journal-title":"Eur J Cancer Clin Oncol"},{"key":"50350391280_CR15","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1200\/JCO.1993.11.6.1156","volume":"11","author":"LM Reyno","year":"1993","unstructured":"Reyno LM, Egorin MJ, Canetta RM, Jodrell DI, Swenerton KD, Pater JL, Burroughs JN, Novak MJ, Sridhara R (1993) Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer. J Clin Oncol 11:1156","journal-title":"J Clin Oncol"},{"key":"50350391280_CR16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1200\/JCO.1987.5.2.185","volume":"5","author":"IE Smith","year":"1987","unstructured":"Smith IE, Evans BD, Gore ME, Vincent MD, Repetto L, Yarnold JR, Ford HT (1987) Carboplatin (Paraplatin; JM8) and etoposide (VP16) as first-line combination therapy for small-cell lung cancer. J Clin Oncol 5:185","journal-title":"J Clin Oncol"},{"key":"50350391280_CR17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/BF00685696","volume":"28","author":"BT Sorensen","year":"1991","unstructured":"Sorensen BT, Str\u00f6mgren A, Jakobsen P, Jakobsen A (1991) Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother Pharmacol 28:337","journal-title":"Cancer Chemother Pharmacol"},{"key":"50350391280_CR18","doi-asserted-by":"crossref","unstructured":"Sorensen BT, Str\u00f6mgren A, Jakobsen P, Jakobsen A (1993) Is creatinine clearance a sufficient measurement for GFR in carboplatin dose calculation (abstract 595)? Proceedings, ECCO 7 Meeting, Jerusalem November 14\u201318","DOI":"10.1016\/0959-8049(93)91217-9"},{"key":"50350391280_CR19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2165\/00003088-199121040-00002","volume":"21","author":"WJF Vijgh Van der","year":"1991","unstructured":"Van der Vijgh WJF (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21:242","journal-title":"Clin Pharmacokinet"},{"key":"50350391280_CR20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2165\/00003495-198937020-00005","volume":"37","author":"AJ Wagstaff","year":"1989","unstructured":"Wagstaff AJ, Ward A, Benfield P, Heel RC (1989) Carboplatin: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs 37:162","journal-title":"Drugs"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s002800050252.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s002800050252\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s002800050252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T10:40:07Z","timestamp":1576665607000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s002800050252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1995,1]]}},"alternative-id":["50350391280"],"URL":"https:\/\/doi.org\/10.1007\/s002800050252","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,1]]}}}